Sagimet Biosciences (SGMT)
Sagimet Biosciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
11.5M
Short interest
settlement 2026-10-15
8.2
Days to cover
+1.5 days vs prior
34.5%
Short share of volume
2026-11-02
2,604
Fails to deliver
settlement 2026-10-13
Thu 12 Nov
Next earnings
estimated date
-$3.8M
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in SGMT is 11,528,274 shares, up 1,265,373 shares over the last month. Over the last 48 readings it ranged from 2,412,557 shares (29 August 2025) to 11,746,200 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 1.4M shares a day that is 8.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/sgmt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 11,528,274 | +3.0% | 1,400,788 | 8.23 |
| 2026-09-30 | 11,189,683 | +9.0% | 1,670,057 | 6.70 |
| 2026-09-15 | 10,262,901 | +1.5% | 971,533 | 10.56 |
| 2026-08-31 | 10,112,756 | -13.9% | 1,055,498 | 9.58 |
| 2026-08-14 | 11,746,200 | +1.3% | 1,713,131 | 6.86 |
| 2026-07-31 | 11,595,503 | +19.0% | 711,090 | 16.31 |
| 2026-07-15 | 9,743,203 | +18.1% | 1,059,366 | 9.20 |
| 2026-06-30 | 8,252,474 | +41.6% | 2,098,756 | 3.93 |
| 2026-06-15 | 5,829,798 | +21.4% | 646,937 | 9.01 |
| 2026-05-29 | 4,804,256 | +14.1% | 826,148 | 5.82 |
| 2026-05-15 | 4,211,720 | -7.1% | 985,380 | 4.27 |
| 2026-04-30 | 4,532,912 | +26.0% | 5,264,584 | 1.00 |
| 2026-04-15 | 3,598,600 | +11.6% | 345,763 | 10.41 |
| 2026-03-31 | 3,225,311 | -15.2% | 410,992 | 7.85 |
| 2026-03-13 | 3,803,560 | +3.9% | 302,673 | 12.57 |
| 2026-02-27 | 3,659,324 | -5.8% | 392,731 | 9.32 |
| 2026-02-13 | 3,886,566 | +14.1% | 833,242 | 4.66 |
| 2026-01-30 | 3,406,374 | +6.3% | 791,467 | 4.30 |
| 2026-01-15 | 3,202,936 | +16.4% | 656,860 | 4.88 |
| 2025-12-31 | 2,752,089 | -7.2% | 590,256 | 4.66 |
| 2025-12-15 | 2,965,683 | -3.4% | 585,599 | 5.06 |
| 2025-11-28 | 3,068,647 | +2.6% | 470,005 | 6.53 |
| 2025-11-14 | 2,989,800 | -4.4% | 479,536 | 6.23 |
| 2025-10-31 | 3,127,997 | +13.7% | 655,979 | 4.77 |
| 2025-10-15 | 2,751,347 | +0.7% | 545,573 | 5.04 |
| 2025-09-30 | 2,731,112 | -12.1% | 566,754 | 4.82 |
| 2025-09-15 | 3,107,193 | +28.8% | 392,327 | 7.92 |
| 2025-08-29 | 2,412,557 | -13.8% | 645,811 | 3.74 |
| 2025-08-15 | 2,798,536 | -12.9% | 654,422 | 4.28 |
| 2025-07-31 | 3,211,457 | -4.9% | 805,295 | 3.99 |
| 2025-07-15 | 3,378,220 | -6.9% | 799,785 | 4.22 |
| 2025-06-30 | 3,629,995 | -4.6% | 1,909,459 | 1.90 |
| 2025-06-13 | 3,805,939 | +3.9% | 5,176,177 | 1.00 |
| 2025-05-30 | 3,661,543 | +2.1% | 361,007 | 10.14 |
| 2025-05-15 | 3,586,791 | -7.7% | 436,789 | 8.21 |
| 2025-04-30 | 3,885,103 | +1.6% | 674,859 | 5.76 |
| 2025-04-15 | 3,825,090 | -3.3% | 776,516 | 4.93 |
| 2025-03-31 | 3,955,058 | -5.7% | 296,786 | 13.33 |
| 2025-03-14 | 4,192,093 | -15.8% | 349,101 | 12.01 |
| 2025-02-28 | 4,975,982 | -9.1% | 594,198 | 8.37 |
| 2025-02-14 | 5,473,072 | +5.7% | 795,076 | 6.88 |
| 2025-01-31 | 5,176,432 | +8.2% | 1,011,742 | 5.12 |
| 2025-01-15 | 4,783,974 | +15.1% | 2,120,292 | 2.26 |
| 2024-12-31 | 4,158,262 | +0.1% | 911,838 | 4.56 |
| 2024-12-13 | 4,153,014 | +0.6% | 507,250 | 8.19 |
| 2024-11-29 | 4,127,051 | -5.4% | 405,937 | 10.17 |
| 2024-11-15 | 4,364,272 | +4.6% | 797,189 | 5.47 |
| 2024-10-31 | 4,171,230 | +4.7% | 819,505 | 5.09 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of SGMT volume is 34.5%, down 32.8 points over the last five sessions. Over the last 30 readings it ranged from 34.5% (2 November 2026) to 80.2% (16 October 2026). The latest reading sits at the bottom of that range. The latest reading is 24.4 points below the 30-session average of 59.0%, on 343K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 119K | 343K | 34.5% | 246 |
| 2026-10-30 | 167K | 347K | 48.1% | 137 |
| 2026-10-29 | 108K | 270K | 39.9% | 100 |
| 2026-10-28 | 160K | 341K | 46.8% | 0 |
| 2026-10-27 | 255K | 396K | 64.4% | 0 |
| 2026-10-26 | 164K | 243K | 67.3% | 501 |
| 2026-10-23 | 200K | 270K | 74.1% | 0 |
| 2026-10-22 | 280K | 361K | 77.6% | 42 |
| 2026-10-21 | 345K | 560K | 61.7% | 0 |
| 2026-10-20 | 404K | 677K | 59.6% | 1,575 |
| 2026-10-19 | 372K | 518K | 71.7% | 303 |
| 2026-10-16 | 285K | 355K | 80.2% | 9,993 |
| 2026-10-15 | 291K | 455K | 63.9% | 0 |
| 2026-10-14 | 493K | 759K | 64.9% | 19,468 |
| 2026-10-13 | 834K | 1.2M | 67.8% | 6,906 |
| 2026-10-12 | 236K | 559K | 42.3% | 900 |
| 2026-10-09 | 165K | 221K | 74.7% | 0 |
| 2026-10-08 | 159K | 397K | 40.0% | 1,053 |
| 2026-10-07 | 130K | 198K | 65.7% | 0 |
| 2026-10-06 | 222K | 302K | 73.4% | 700 |
| 2026-10-05 | 450K | 702K | 64.0% | 0 |
| 2026-10-02 | 351K | 574K | 61.2% | 0 |
| 2026-10-01 | 414K | 684K | 60.5% | 0 |
| 2026-09-30 | 1.3M | 2.4M | 53.3% | 10,766 |
| 2026-09-29 | 135K | 245K | 55.2% | 0 |
| 2026-09-28 | 243K | 441K | 55.1% | 0 |
| 2026-09-25 | 319K | 481K | 66.2% | 22,328 |
| 2026-09-24 | 927K | 1.7M | 54.4% | 109,829 |
| 2026-09-23 | 186K | 486K | 38.2% | 104 |
| 2026-09-22 | 157K | 366K | 43.0% | 800 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in SGMT is 2,604 shares, down 1,614 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (9 July 2026) to 51,884 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 2,604 | $8.80 | $23K |
| 2026-10-01 | 4,218 | $9.88 | $42K |
| 2026-09-30 | 50 | $9.33 | $467 |
| 2026-09-28 | 4,570 | $9.24 | $42K |
| 2026-09-25 | 3,929 | $9.11 | $36K |
| 2026-09-24 | 1,168 | $10.42 | $12K |
| 2026-09-18 | 179 | $11.17 | $2K |
| 2026-08-24 | 500 | $10.25 | $5K |
| 2026-08-11 | 1,151 | $9.57 | $11K |
| 2026-08-06 | 867 | $8.64 | $7K |
| 2026-08-05 | 2,897 | $7.99 | $23K |
| 2026-08-04 | 1,932 | $7.15 | $14K |
| 2026-08-03 | 21,148 | $7.11 | $150K |
| 2026-07-28 | 48 | $7.45 | $358 |
| 2026-07-23 | 1,086 | $7.05 | $8K |
| 2026-07-20 | 2,300 | $7.82 | $18K |
| 2026-07-15 | 6 | $7.76 | $47 |
| 2026-07-09 | 6 | $7.44 | $45 |
| 2026-07-08 | 55 | $7.69 | $423 |
| 2026-07-07 | 121 | $7.74 | $937 |
| 2026-07-02 | 4,224 | $7.46 | $32K |
| 2026-07-01 | 767 | $7.73 | $6K |
| 2026-06-30 | 48,625 | $7.79 | $379K |
| 2026-06-29 | 51,884 | $7.06 | $366K |
| 2026-06-23 | 2,518 | $7.10 | $18K |
| 2026-06-18 | 462 | $6.53 | $3K |
| 2026-06-17 | 20,438 | $6.30 | $129K |
| 2026-05-13 | 1,515 | $7.65 | $12K |
| 2026-04-29 | 1,102 | $8.75 | $10K |
| 2026-04-28 | 11,570 | $8.12 | $94K |
Insider trades
SEC Form 4, newest first. JSONInsiders at SGMT reported 2 open-market sells worth $3.8M in the last 90 days and no open-market buys. Latest filing: Kemble George (Director) on 2026-08-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Kemble George | Director | Sell | 351K | $10.23 | $3.6M | 62K |
| 2026-08-14 | Kemble George | Director | Exercise or conversion | 24K | $6.36 | $155K | 413K |
| 2026-08-14 | Kemble George | Director | Exercise or conversion | 327K | $6.36 | $2.1M | 389K |
| 2026-08-11 | Kemble George | Director | Sell | 20K | $9.95 | $201K | 62K |
| 2026-08-11 | Kemble George | Director | Exercise or conversion | 10K | $6.36 | $66K | 82K |
| 2026-08-11 | Kemble George | Director | Exercise or conversion | 10K | $6.36 | $62K | 72K |
| 2026-07-20 | Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 11K | $7.76 | $82K | 224K |
| 2026-07-20 | Kemble George | Director | Sell | 19K | $7.46 | $141K | 62K |
| 2026-07-20 | Happel David | President & CEO | Sell | 64K | $7.76 | $497K | 742K |
| 2026-02-19 | Rozek Elizabeth | Chief Legal & Admin. Officer | Grant | 44K | $0.00 | $0 | 235K |
| 2026-02-19 | Martins Eduardo Bruno | Chief Medical Officer | Grant | 44K | $0.00 | $0 | 147K |
| 2026-02-19 | Happel David | President & CEO | Grant | 128K | $0.00 | $0 | 806K |
| 2026-02-19 | Chauche Thierry | Chief Financial Officer | Grant | 44K | $0.00 | $0 | 60K |
| 2026-02-10 | Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 3K | $5.36 | $14K | 191K |
| 2026-02-10 | Martins Eduardo Bruno | Chief Medical Officer | Sell | 4K | $5.36 | $20K | 103K |
| 2026-02-10 | Happel David | President & CEO | Sell | 12K | $5.36 | $65K | 678K |
| 2026-02-10 | Chauche Thierry | Chief Financial Officer | Sell | 1K | $5.36 | $7K | 16K |
| 2025-11-20 | Kemble George | Executive Chairman | Sell | 38K | $7.69 | $290K | 81K |
| 2025-11-04 | Rozek Elizabeth | Chief Legal & Admin. Officer | Grant | 10K | $0.00 | $0 | 194K |
| 2025-07-21 | Rozek Elizabeth | General Counsel and CCO | Sell | 11K | $9.13 | $98K | 184K |
| 2025-07-21 | Martins Eduardo Bruno | Chief Medical Officer | Sell | 8K | $9.13 | $76K | 107K |
| 2025-07-21 | Happel David | President & CEO | Sell | 65K | $9.13 | $598K | 690K |
| 2025-02-06 | Chauche Thierry | Chief Financial Officer | Grant | 17K | $0.00 | $0 | 17K |
| 2025-02-06 | Rozek Elizabeth | General Counsel and CCO | Grant | 34K | $0.00 | $0 | 195K |
| 2025-02-06 | Happel David | President & CEO | Grant | 116K | $0.00 | $0 | 755K |
| 2025-02-06 | Martins Eduardo Bruno | Chief Medical Officer | Grant | 34K | $0.00 | $0 | 115K |
| 2024-07-23 | Kemble George | Executive Chairman | Sell | 24K | $3.17 | $75K | 119K |
| 2024-07-19 | Kemble George | Executive Chairman | Sell | 14K | $3.10 | $44K | 142K |
| 2024-07-19 | Rozek Elizabeth | General Counsel and CCO | Sell | 11K | $3.10 | $34K | 161K |
| 2024-07-19 | Martins Eduardo Bruno | Chief Medical Officer | Sell | 8K | $3.10 | $26K | 81K |
| 2024-03-26 | Happel David | President & CEO | Buy | 12K | $5.27 | $64K | 639K |
| 2024-01-29 | SANDELL SCOTT D | 10% owner | Other transaction | 261K | $0.00 | $0 | 0 |
| 2024-01-29 | KERINS PATRICK J | 10% owner | Other transaction | 261K | $0.00 | $0 | 0 |
| 2024-01-29 | BASKETT FOREST | 10% owner | Other transaction | 261K | $0.00 | $0 | 261K |
| 2024-01-29 | NEW ENTERPRISE ASSOCIATES 13 LP | TenPercentOwner | Other transaction | 850K | $0.00 | $0 | 3.0M |
| 2024-01-29 | NEA 13 GP, Ltd | TenPercentOwner | Other transaction | 261K | $0.00 | $0 | 261K |
| 2024-01-29 | NEA 13 GP, Ltd | TenPercentOwner | Other transaction | 850K | $0.00 | $0 | 3.0M |
| 2024-01-29 | BASKETT FOREST | TenPercentOwner | Other transaction | 850K | $0.00 | $0 | 3.0M |
| 2024-01-29 | BASKETT FOREST | TenPercentOwner | Other transaction | 11K | $0.00 | $0 | 11K |
| 2024-01-29 | BASKETT FOREST | TenPercentOwner | Other transaction | 261K | $0.00 | $0 | 0 |
| 2024-01-29 | KERINS PATRICK J | TenPercentOwner | Other transaction | 850K | $0.00 | $0 | 3.0M |
| 2024-01-29 | KERINS PATRICK J | TenPercentOwner | Other transaction | 261K | $0.00 | $0 | 261K |
| 2024-01-29 | KERINS PATRICK J | TenPercentOwner | Other transaction | 13K | $0.00 | $0 | 13K |
| 2024-01-29 | SANDELL SCOTT D | TenPercentOwner | Other transaction | 850K | $0.00 | $0 | 3.0M |
| 2024-01-29 | SANDELL SCOTT D | TenPercentOwner | Other transaction | 7K | $0.00 | $0 | 7K |
| 2024-01-29 | SANDELL SCOTT D | TenPercentOwner | Other transaction | 261K | $0.00 | $0 | 261K |
| 2023-12-07 | Happel David | President & CEO | Buy | 2K | $4.10 | $7K | 627K |
| 2023-11-17 | Happel David | President & CEO | Grant | 625K | $0.00 | $0 | 626K |
| 2023-11-17 | Kemble George | Executive Chairman | Grant | 151K | $0.00 | $0 | 156K |
| 2023-11-17 | Martins Eduardo Bruno | Chief Medical Officer | Grant | 90K | $0.00 | $0 | 90K |
| 2023-11-17 | Rozek Elizabeth | General Counsel and CCO | Grant | 171K | $0.00 | $0 | 171K |
| 2023-11-16 | Happel David | President & CEO | Buy | 590 | $2.35 | $1K | 590 |
| 2023-09-07 | Kemble George | Executive Chairman | Exercise or conversion | 6K | $0.79 | $4K | 6K |
| 2023-07-18 | Parsey Merdad | Director | Returned to company | 9K | price not stated in the filing | not stated | 0 |
| 2023-07-18 | Parsey Merdad | Director | Grant | 9K | price not stated in the filing | not stated | 9K |
| 2023-07-18 | Parsey Merdad | Director | Conversion | 4K | price not stated in the filing | not stated | 13K |
| 2023-07-18 | Wu Jinzi Jason | Director | Conversion | 1.7M | price not stated in the filing | not stated | 1.7M |
| 2023-07-18 | SEIDENBERG BETH C | Director | Buy | 47K | $16.00 | $750K | 47K |
| 2023-07-18 | SEIDENBERG BETH C | Director | Returned to company | 39K | price not stated in the filing | not stated | 0 |
| 2023-07-18 | SEIDENBERG BETH C | Director | Grant | 39K | price not stated in the filing | not stated | 39K |
| 2023-07-18 | SEIDENBERG BETH C | Director | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2023-07-18 | SEIDENBERG BETH C | Director | Conversion | 85K | price not stated in the filing | not stated | 85K |
| 2023-07-18 | KPCB PANDEMIC & BIO DEFENSE FUND LLC | TenPercentOwner | Other transaction | 39K | price not stated in the filing | not stated | 39K |
| 2023-07-18 | KPCB PANDEMIC & BIO DEFENSE FUND LLC | TenPercentOwner | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2023-07-18 | KERINS PATRICK J | TenPercentOwner | Other transaction | 38K | price not stated in the filing | not stated | 38K |
| 2023-07-18 | KERINS PATRICK J | TenPercentOwner | Conversion | 3.8M | price not stated in the filing | not stated | 3.8M |
| 2023-07-18 | KERINS PATRICK J | TenPercentOwner | Exercise (in or at the money) | 13K | $0.79 | $11K | 3.8M |
| 2023-07-18 | KERINS PATRICK J | TenPercentOwner | Sell | 662 | $16.00 | $11K | 3.8M |
| 2023-07-18 | KERINS PATRICK J | TenPercentOwner | Buy | 30K | $16.00 | $480K | 3.9M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for SGMT worth $3.9M at the prices reported; 2 in the last 90 days worth $3.5M. Latest: GEORGE KEMBLE filed on 2026-08-14 to sell 350,987 shares ($3.3M) from 2026-08-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-14 | GEORGE KEMBLEDirector | 351K | $3.3M | 0.570% | 2026-08-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-11 | GEORGE KEMBLEDirector | 20K | $193K | 0.033% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-20 | GEORGE KEMBLEDirector, Officer | 19K | $147K | 0.031% | 2026-07-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-20 | GEORGE KEMBLEDirector, Officer | 38K | $296K | 0.122% | 2025-11-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON10 holders report 5% or more of SGMT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.8% of the class (4,751,186 shares), filed 2026-07-30 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G | Commodore Capital LPpartnership, investment adviser | 5.5M | 7.6% | 2026-09-30 |
| 2026-10-07 | 13G | Commodore Capital Master LPpartnership | 5.5M | 7.6% | 2026-09-30 |
| 2026-10-07 | 13G | Robert Egen Atkinsonparent holding company, individual | 5.5M | 7.6% | 2026-09-30 |
| 2026-10-07 | 13G | Michael Kramarzparent holding company, individual | 5.5M | 7.6% | 2026-09-30 |
| 2026-08-14 | 13G | BALYASNY ASSET MANAGEMENT L.P.investment adviser, partnership | 3.6M | 5.9% | 2026-06-30 |
| 2026-08-14 | 13G | BAM GP LLCparent holding company, other entity | 3.6M | 5.9% | 2026-06-30 |
| 2026-08-14 | 13G | Balyasny Asset Management Holdings LPparent holding company, partnership | 3.6M | 5.9% | 2026-06-30 |
| 2026-08-14 | 13G | Dames GP LLCparent holding company, other entity | 3.6M | 5.9% | 2026-06-30 |
| 2026-08-14 | 13G | Dmitry Balyasnyparent holding company, individual | 3.6M | 5.9% | 2026-06-30 |
| 2026-07-30 | 13G | BlackRock, Inc.parent holding company | 4.8M | 7.8% | 2026-06-30 |
| 2025-12-18 | 13G/Ano. 1 | KPCB Pandemic and Bio Defense Fund, LLCother entity | 0 | 0.0% | 2025-12-18 |
| 2025-12-18 | 13G/Ano. 1 | KPCB PBD Associates, LLCother entity | 0 | 0.0% | 2025-12-18 |
| 2025-11-14 | 13G/Ano. 1 | Woodline Partners LPinvestment adviser, partnership | 1.5M | 4.8% | 2025-09-30 |
13F holders
Tracked managers holding SGMT at their latest 13F. JSON5 of the 30 tracked managers held SGMT at their latest 13F, $11.5M in total at quarter-end prices. Millennium Management is the largest at $7.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 937K | $7.2M | 0.00% | +75K |
| Renaissance Technologies | 2026-06-30 | 347K | $2.7M | 0.00% | -279K |
| Citadel Advisors | 2026-06-30 | 105K | $809K | 0.00% | +36K |
| Two Sigma Investments | 2026-06-30 | 82K | $633K | 0.00% | +42K |
| D. E. Shaw & Co. | 2026-06-30 | 22K | $171K | 0.00% | -389K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Sagimet Biosciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Sagimet Biosciences (SGMT), SEC CIK 1400118, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1400118Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of SGMT is sold short?
11,528,274 shares were held short at the 2026-10-15 settlement, 8.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SGMT's daily short volume?
On 2026-11-02, 118,606 of the 343,276 SGMT shares reported to FINRA were sold short, 34.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SGMT have fails to deliver?
The SEC's latest file shows 2,604 SGMT shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are SGMT insiders buying or selling?
Insiders at SGMT reported 2 open-market sells worth $3.8M in the last 90 days and no open-market buys. Latest filing: Kemble George (Director) on 2026-08-14.
Have SGMT insiders filed to sell?
4 Form 144 notices on file for SGMT worth $3.9M at the prices reported; 2 in the last 90 days worth $3.5M. Latest: GEORGE KEMBLE filed on 2026-08-14 to sell 350,987 shares ($3.3M) from 2026-08-14.
Who owns 5% or more of SGMT?
10 holders report 5% or more of SGMT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.8% of the class (4,751,186 shares), filed 2026-07-30 for an event on 2026-06-30.
Which tracked 13F managers own SGMT?
5 of the 30 tracked 13F managers held SGMT shares at their latest filing, $11.5M in all. The largest: Izzy Englander's Millennium Management (937K shares, $7.2M), Renaissance Technologies (347K shares, $2.7M), Ken Griffin's Citadel Advisors (105K shares, $809K), Two Sigma Investments (82K shares, $633K), D. E. Shaw & Co. (22K shares, $171K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.